ID   MK07_HUMAN              Reviewed;         816 AA.
AC   Q13164; Q16634; Q59F50; Q6QLU7; Q7L4P4; Q969G1; Q96G51;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   12-APR-2017, entry version 173.
DE   RecName: Full=Mitogen-activated protein kinase 7;
DE            Short=MAP kinase 7;
DE            Short=MAPK 7;
DE            EC=2.7.11.24;
DE   AltName: Full=Big MAP kinase 1;
DE            Short=BMK-1;
DE   AltName: Full=Extracellular signal-regulated kinase 5;
DE            Short=ERK-5;
GN   Name=MAPK7; Synonyms=BMK1, ERK5, PRKM7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Placenta;
RX   PubMed=7646528; DOI=10.1006/bbrc.1995.2189;
RA   Lee J.-D., Ulevitch R.J., Han J.;
RT   "Primary structure of BMK1: a new mammalian map kinase.";
RL   Biochem. Biophys. Res. Commun. 213:715-724(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH MAP2K5, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=7759517; DOI=10.1074/jbc.270.21.12665;
RA   Zhou G., Bao Z.Q., Dixon J.E.;
RT   "Components of a new human protein kinase signal transduction
RT   pathway.";
RL   J. Biol. Chem. 270:12665-12669(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RX   PubMed=15716121; DOI=10.1016/j.gene.2004.11.011;
RA   McCaw B.J., Chow S.Y., Wong E.S.M., Tan K.L., Guo H., Guy G.R.;
RT   "Identification and characterization of mErk5-T, a novel Erk5/Bmk1
RT   splice variant.";
RL   Gene 345:183-190(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Spleen;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Muscle, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-35; 75-98; 119-131; 198-205; 296-343; 377-392;
RP   468-485; 489-505; 544-571; 720-735 AND 798-816, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Fleming J., Leug H.Y.;
RL   Submitted (JAN-2010) to UniProtKB.
RN   [8]
RP   FUNCTION, ENZYME REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   219-THR--TYR-221.
RX   PubMed=9384584; DOI=10.1093/emboj/16.23.7054;
RA   Kato Y., Kravchenko V.V., Tapping R.I., Han J., Ulevitch R.J.,
RA   Lee J.-D.;
RT   "BMK1/ERK5 regulates serum-induced early gene expression through
RT   transcription factor MEF2C.";
RL   EMBO J. 16:7054-7066(1997).
RN   [9]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=9790194; DOI=10.1038/27234;
RA   Kato Y., Tapping R.I., Huang S., Watson M.H., Ulevitch R.J.,
RA   Lee J.-D.;
RT   "Bmk1/Erk5 is required for cell proliferation induced by epidermal
RT   growth factor.";
RL   Nature 395:713-716(1998).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH SGK1.
RX   PubMed=11254654; DOI=10.1074/jbc.C000838200;
RA   Hayashi M., Tapping R.I., Chao T.H., Lo J.F., King C.C., Yang Y.,
RA   Lee J.D.;
RT   "BMK1 mediates growth factor-induced cell proliferation through direct
RT   cellular activation of serum and glucocorticoid-inducible kinase.";
RL   J. Biol. Chem. 276:8631-8634(2001).
RN   [11]
RP   FUNCTION.
RX   PubMed=11278431; DOI=10.1074/jbc.M008748200;
RA   Dong F., Gutkind J.S., Larner A.C.;
RT   "Granulocyte colony-stimulating factor induces ERK5 activation, which
RT   is differentially regulated by protein-tyrosine kinases and protein
RT   kinase C. Regulation of cell proliferation and survival.";
RL   J. Biol. Chem. 276:10811-10816(2001).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-720 AND THR-733, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   INTERACTION WITH HSP90AB1.
RX   PubMed=23428871; DOI=10.1128/MCB.01246-12;
RA   Erazo T., Moreno A., Ruiz-Babot G., Rodriguez-Asiain A., Morrice N.A.,
RA   Espadamala J., Bayascas J.R., Gomez N., Lizcano J.M.;
RT   "Canonical and kinase activity-independent mechanisms for
RT   extracellular signal-regulated kinase 5 (ERK5) nuclear translocation
RT   require dissociation of Hsp90 from the ERK5-Cdc37 complex.";
RL   Mol. Cell. Biol. 33:1671-1686(2013).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH
RP   PML.
RX   PubMed=22869143; DOI=10.1038/onc.2012.332;
RA   Yang Q., Liao L., Deng X., Chen R., Gray N.S., Yates J.R. III,
RA   Lee J.D.;
RT   "BMK1 is involved in the regulation of p53 through disrupting the PML-
RT   MDM2 interaction.";
RL   Oncogene 32:3156-3164(2013).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-535 AND ALA-550.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Plays a role in various cellular processes such as
CC       proliferation, differentiation and cell survival. The upstream
CC       activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it
CC       translocates to the nucleus and phosphorylates various downstream
CC       targets including MEF2C. EGF activates MAPK7 through a Ras-
CC       independent and MAP2K5-dependent pathway. May have a role in
CC       muscle cell differentiation. May be important for endothelial
CC       function and maintenance of blood vessel integrity. MAP2K5 and
CC       MAPK7 interact specifically with one another and not with
CC       MEK1/ERK1 or MEK2/ERK2 pathways. Phosphorylates SGK1 at Ser-78 and
CC       this is required for growth factor-induced cell cycle progression.
CC       Involved in the regulation of p53/TP53 by disrupting the PML-MDM2
CC       interaction. {ECO:0000269|PubMed:11254654,
CC       ECO:0000269|PubMed:11278431, ECO:0000269|PubMed:22869143,
CC       ECO:0000269|PubMed:9384584, ECO:0000269|PubMed:9790194}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activated by tyrosine and threonine
CC       phosphorylation (By similarity). Activated in response to
CC       hyperosmolarity, hydrogen peroxide, and epidermal growth factor
CC       (EGF). {ECO:0000250, ECO:0000269|PubMed:9384584,
CC       ECO:0000269|PubMed:9790194}.
CC   -!- SUBUNIT: Interacts with MAP2K5. Forms oligomers (By similarity).
CC       Interacts with MEF2A, MEF2C and MEF2D; the interaction
CC       phosphorylates the MEF2s and enhances transcriptional activity of
CC       MEF2A, MEF2C but not MEF2D (By similarity). Interacts with SGK1.
CC       Preferentially interacts with PML isoform PML-4 but shows
CC       interaction also with its other isoforms: isoform PML-1, isoform
CC       PML-2, isoform PML-3 and isoform PML-6. Interacts (via N-terminal
CC       half) with HSP90AB1-CDC37 chaperone complex in resting cells; the
CC       interaction is MAP2K5-independent and prevents MAPK7 from
CC       ubiquitination and proteasomal degradation (PubMed:23428871).
CC       {ECO:0000250, ECO:0000269|PubMed:11254654,
CC       ECO:0000269|PubMed:22869143, ECO:0000269|PubMed:23428871,
CC       ECO:0000269|PubMed:7759517}.
CC   -!- INTERACTION:
CC       Q13163:MAP2K5; NbExp=4; IntAct=EBI-1213983, EBI-307294;
CC       P29590:PML; NbExp=6; IntAct=EBI-1213983, EBI-295890;
CC       Q5TZN3:UBE2C; NbExp=3; IntAct=EBI-1213983, EBI-10247554;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body.
CC       Note=Translocates to the nucleus upon activation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q13164-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13164-2; Sequence=VSP_035198;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q13164-3; Sequence=VSP_035200;
CC       Name=4;
CC         IsoId=Q13164-4; Sequence=VSP_035199, VSP_035200;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in many adult tissues. Abundant in
CC       heart, placenta, lung, kidney and skeletal muscle. Not detectable
CC       in liver. {ECO:0000269|PubMed:7759517}.
CC   -!- DOMAIN: The second proline-rich region may interact with actin
CC       targeting the kinase to a specific location in the cell.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-219 and Tyr-221, which activates
CC       the enzyme (By similarity). Autophosphorylated in vitro on
CC       threonine and tyrosine residues when the C-terminal part of the
CC       kinase, which could have a regulatory role, is absent.
CC       {ECO:0000250, ECO:0000269|PubMed:22869143}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA81381.1; Type=Frameshift; Positions=19, 32; Evidence={ECO:0000305};
CC       Sequence=BAD92848.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK7ID41294ch17p11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U29725; AAA82931.1; -; mRNA.
DR   EMBL; U29726; AAA82932.1; -; mRNA.
DR   EMBL; U29727; AAA82933.1; -; Genomic_DNA.
DR   EMBL; U25278; AAA81381.1; ALT_FRAME; mRNA.
DR   EMBL; AY534741; AAS38577.1; -; mRNA.
DR   EMBL; AB209611; BAD92848.1; ALT_INIT; mRNA.
DR   EMBL; CH471212; EAW50883.1; -; Genomic_DNA.
DR   EMBL; CH471212; EAW50886.1; -; Genomic_DNA.
DR   EMBL; BC007404; AAH07404.1; -; mRNA.
DR   EMBL; BC007992; AAH07992.1; -; mRNA.
DR   EMBL; BC009963; AAH09963.1; -; mRNA.
DR   EMBL; BC030134; AAH30134.1; -; mRNA.
DR   CCDS; CCDS11206.1; -. [Q13164-1]
DR   CCDS; CCDS11207.1; -. [Q13164-2]
DR   PIR; B56708; B56708.
DR   RefSeq; NP_002740.2; NM_002749.3. [Q13164-1]
DR   RefSeq; NP_620601.1; NM_139032.2. [Q13164-2]
DR   RefSeq; NP_620602.2; NM_139033.2. [Q13164-1]
DR   RefSeq; NP_620603.2; NM_139034.2. [Q13164-1]
DR   RefSeq; XP_011522259.1; XM_011523957.2. [Q13164-2]
DR   UniGene; Hs.150136; -.
DR   PDB; 2Q8Y; X-ray; 2.00 A; B=215-223.
DR   PDB; 4B99; X-ray; 2.80 A; A=1-397.
DR   PDB; 4IC7; X-ray; 2.60 A; A/D=1-431.
DR   PDB; 4IC8; X-ray; 2.80 A; A/B=1-431.
DR   PDB; 4ZSG; X-ray; 1.79 A; A=47-393.
DR   PDB; 4ZSJ; X-ray; 2.48 A; A=50-393.
DR   PDB; 4ZSL; X-ray; 2.25 A; A=53-393.
DR   PDB; 5BYY; X-ray; 2.79 A; A=49-394.
DR   PDB; 5BYZ; X-ray; 1.65 A; A=48-395.
DR   PDBsum; 2Q8Y; -.
DR   PDBsum; 4B99; -.
DR   PDBsum; 4IC7; -.
DR   PDBsum; 4IC8; -.
DR   PDBsum; 4ZSG; -.
DR   PDBsum; 4ZSJ; -.
DR   PDBsum; 4ZSL; -.
DR   PDBsum; 5BYY; -.
DR   PDBsum; 5BYZ; -.
DR   ProteinModelPortal; Q13164; -.
DR   SMR; Q13164; -.
DR   BioGrid; 111584; 64.
DR   IntAct; Q13164; 35.
DR   STRING; 9606.ENSP00000311005; -.
DR   BindingDB; Q13164; -.
DR   ChEMBL; CHEMBL5332; -.
DR   GuidetoPHARMACOLOGY; 2093; -.
DR   iPTMnet; Q13164; -.
DR   PhosphoSitePlus; Q13164; -.
DR   BioMuta; MAPK7; -.
DR   DMDM; 205371766; -.
DR   EPD; Q13164; -.
DR   MaxQB; Q13164; -.
DR   PaxDb; Q13164; -.
DR   PeptideAtlas; Q13164; -.
DR   PRIDE; Q13164; -.
DR   DNASU; 5598; -.
DR   Ensembl; ENST00000299612; ENSP00000299612; ENSG00000166484. [Q13164-2]
DR   Ensembl; ENST00000308406; ENSP00000311005; ENSG00000166484. [Q13164-1]
DR   Ensembl; ENST00000395602; ENSP00000378966; ENSG00000166484. [Q13164-1]
DR   Ensembl; ENST00000395604; ENSP00000378968; ENSG00000166484. [Q13164-1]
DR   GeneID; 5598; -.
DR   KEGG; hsa:5598; -.
DR   UCSC; uc002gvn.4; human. [Q13164-1]
DR   CTD; 5598; -.
DR   DisGeNET; 5598; -.
DR   GeneCards; MAPK7; -.
DR   HGNC; HGNC:6880; MAPK7.
DR   HPA; CAB018561; -.
DR   HPA; HPA031031; -.
DR   MIM; 602521; gene.
DR   neXtProt; NX_Q13164; -.
DR   OpenTargets; ENSG00000166484; -.
DR   PharmGKB; PA30625; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   eggNOG; ENOG410XNY0; LUCA.
DR   GeneTree; ENSGT00550000074298; -.
DR   HOVERGEN; HBG108137; -.
DR   InParanoid; Q13164; -.
DR   KO; K04464; -.
DR   OMA; QCESATP; -.
DR   OrthoDB; EOG091G08QL; -.
DR   PhylomeDB; Q13164; -.
DR   TreeFam; TF105099; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-198765; Signalling to ERK5.
DR   Reactome; R-HSA-202670; ERKs are inactivated.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   SignaLink; Q13164; -.
DR   SIGNOR; Q13164; -.
DR   ChiTaRS; MAPK7; human.
DR   GeneWiki; MAPK7; -.
DR   GenomeRNAi; 5598; -.
DR   PRO; PR:Q13164; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000166484; -.
DR   CleanEx; HS_MAPK7; -.
DR   ExpressionAtlas; Q13164; baseline and differential.
DR   Genevisible; Q13164; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004707; F:MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0019933; P:cAMP-mediated signaling; NAS:BHF-UCL.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IGI:BHF-UCL.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IMP:BHF-UCL.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:UniProtKB.
DR   GO; GO:0030821; P:negative regulation of cAMP catabolic process; NAS:BHF-UCL.
DR   GO; GO:0051344; P:negative regulation of cyclic-nucleotide phosphodiesterase activity; NAS:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0070377; P:negative regulation of ERK5 cascade; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IGI:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IGI:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0051534; P:negative regulation of NFAT protein import into nucleus; IEA:Ensembl.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; IGI:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IGI:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IGI:BHF-UCL.
DR   GO; GO:0036003; P:positive regulation of transcription from RNA polymerase II promoter in response to stress; IMP:BHF-UCL.
DR   GO; GO:0045765; P:regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell cycle; Complete proteome; Cytoplasm; Differentiation;
KW   Direct protein sequencing; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000269|Ref.7}.
FT   CHAIN         2    816       Mitogen-activated protein kinase 7.
FT                                /FTId=PRO_0000186260.
FT   DOMAIN       55    347       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      61     69       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        2     77       Required for cytoplasmic targeting.
FT                                {ECO:0000250}.
FT   REGION       78    139       Required for binding to MAP2K5.
FT                                {ECO:0000250}.
FT   REGION      140    406       Necessary for oligomerization.
FT                                {ECO:0000250}.
FT   REGION      407    806       May not be required for kinase activity;
FT                                required to stimulate MEF2C activity.
FT                                {ECO:0000250}.
FT   MOTIF       219    221       TXY.
FT   MOTIF       505    539       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   COMPBIAS    338    341       Poly-Ala.
FT   COMPBIAS    403    694       Pro-rich.
FT   COMPBIAS    513    543       Arg-rich.
FT   ACT_SITE    182    182       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      84     84       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine. {ECO:0000269|Ref.7}.
FT   MOD_RES     720    720       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     733    733       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   VAR_SEQ       1    139       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035198.
FT   VAR_SEQ       1    133       MAEPLKEEDGEDGSAEPPGPVKAEPAHTAASVAAKNLALLK
FT                                ARSFDVTFDVGDEYEIIETIGNGAYGVVSSARRRLTGQQVA
FT                                IKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRP
FT                                TVPYGEFKSV -> MLFFHTMPSAPMGSQGKAVTCLESEGC
FT                                GEDGACPWSVIRPTHASLLPSPSS (in isoform 4).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_035199.
FT   VAR_SEQ     493    816       DGPSAPLEAPEPRKPVTAQERQREREEKRRRRQERAKEREK
FT                                RRQERERKERGAGASGGPSTDPLAGLVLSDNDRSLLERWTR
FT                                MARPAAPALTSVPAPAPAPTPTPTPVQPTSPPPGPVAQPTG
FT                                PQPQSAGSTSGPVPQPACPPPGPAPHPTGPPGPIPVPAPPQ
FT                                IATSTSLLAAQSLVPPPGLPGSSTPGVLPYFPPGLPPPDAG
FT                                GAPQSSMSESPDVNLVTQQLSKSQVEDPLPPVFSGTPKGSG
FT                                AGYGVGFDLEEFLNQSFDMGVADGPQDGQADSASLSASLLA
FT                                DWLEGHGMNPADIESLQREIQMDSPMLLADLPDLQDP ->
FT                                GALWAGRVGRGETWTWTRLQAFTFSPAQLPRKWPQRTPGGS
FT                                (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:15716121,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_035200.
FT   VARIANT     535    535       R -> H. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046225.
FT   VARIANT     550    550       G -> A (in dbSNP:rs56388327).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042257.
FT   MUTAGEN     219    221       TEY->AEF: Loss activation by MAP2K5.
FT                                {ECO:0000269|PubMed:9384584}.
FT   CONFLICT    610    610       V -> L (in Ref. 1; AAA81381).
FT                                {ECO:0000305}.
FT   TURN         45     48       {ECO:0000244|PDB:4IC8}.
FT   STRAND       53     64       {ECO:0000244|PDB:5BYZ}.
FT   STRAND       67     74       {ECO:0000244|PDB:5BYZ}.
FT   TURN         75     77       {ECO:0000244|PDB:5BYZ}.
FT   STRAND       80     86       {ECO:0000244|PDB:5BYZ}.
FT   TURN         87     90       {ECO:0000244|PDB:5BYZ}.
FT   HELIX        93    108       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      117    120       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       127    129       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      133    137       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      141    143       {ECO:0000244|PDB:5BYY}.
FT   HELIX       144    148       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      150    152       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       156    175       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       185    187       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      188    190       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      196    198       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       214    216       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       219    221       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       225    227       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       230    234       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       242    257       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       267    278       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       283    287       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      288    290       {ECO:0000244|PDB:4IC8}.
FT   HELIX       292    300       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       309    312       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      313    316       {ECO:0000244|PDB:5BYY}.
FT   HELIX       318    327       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       332    334       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       338    342       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       345    347       {ECO:0000244|PDB:5BYZ}.
FT   TURN        348    350       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       353    355       {ECO:0000244|PDB:5BYZ}.
FT   HELIX       366    369       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      370    372       {ECO:0000244|PDB:4IC7}.
FT   HELIX       374    393       {ECO:0000244|PDB:5BYZ}.
FT   STRAND      396    398       {ECO:0000244|PDB:4IC7}.
SQ   SEQUENCE   816 AA;  88386 MW;  27729FE31658CE3B CRC64;
     MAEPLKEEDG EDGSAEPPGP VKAEPAHTAA SVAAKNLALL KARSFDVTFD VGDEYEIIET
     IGNGAYGVVS SARRRLTGQQ VAIKKIPNAF DVVTNAKRTL RELKILKHFK HDNIIAIKDI
     LRPTVPYGEF KSVYVVLDLM ESDLHQIIHS SQPLTLEHVR YFLYQLLRGL KYMHSAQVIH
     RDLKPSNLLV NENCELKIGD FGMARGLCTS PAEHQYFMTE YVATRWYRAP ELMLSLHEYT
     QAIDLWSVGC IFGEMLARRQ LFPGKNYVHQ LQLIMMVLGT PSPAVIQAVG AERVRAYIQS
     LPPRQPVPWE TVYPGADRQA LSLLGRMLRF EPSARISAAA ALRHPFLAKY HDPDDEPDCA
     PPFDFAFDRE ALTRERIKEA IVAEIEDFHA RREGIRQQIR FQPSLQPVAS EPGCPDVEMP
     SPWAPSGDCA MESPPPAPPP CPGPAPDTID LTLQPPPPVS EPAPPKKDGA ISDNTKAALK
     AALLKSLRSR LRDGPSAPLE APEPRKPVTA QERQREREEK RRRRQERAKE REKRRQERER
     KERGAGASGG PSTDPLAGLV LSDNDRSLLE RWTRMARPAA PALTSVPAPA PAPTPTPTPV
     QPTSPPPGPV AQPTGPQPQS AGSTSGPVPQ PACPPPGPAP HPTGPPGPIP VPAPPQIATS
     TSLLAAQSLV PPPGLPGSST PGVLPYFPPG LPPPDAGGAP QSSMSESPDV NLVTQQLSKS
     QVEDPLPPVF SGTPKGSGAG YGVGFDLEEF LNQSFDMGVA DGPQDGQADS ASLSASLLAD
     WLEGHGMNPA DIESLQREIQ MDSPMLLADL PDLQDP
//
